MwanzoORMP • NASDAQ
add
Oramed Pharmaceuticals, Inc.
$Â 2.22
Baada ya Saa za Kazi:(1.35%)+0.030
$Â 2.25
Imefungwa: 6 Jun, 20:00:00 GMT -4 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$Â 2.15
Bei za siku
$Â 2.07 - $Â 2.25
Bei za mwaka
$Â 1.82 - $Â 3.09
Thamani ya kampuni katika soko
90.69M USD
Wastani wa hisa zilizouzwa
elfu 76.74
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Mac 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 2.00M | — |
Matumizi ya uendeshaji wa biashara | 4.51M | 52.36% |
Mapato halisi | -7.64M | -597.53% |
Kiwango cha faida halisi | -382.10 | — |
Mapato kwa kila hisa | — | — |
EBITDA | -4.47M | -53.82% |
Asilimia ya kodi ya mapato | -8.27% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Mac 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 130.64M | -26.02% |
Jumla ya mali | 147.54M | -27.55% |
Jumla ya dhima | 7.64M | -79.84% |
Jumla ya hisa | 139.89M | — |
hisa zilizosalia | 40.85M | — |
Uwiano wa bei na thamani | 0.62 | — |
Faida inayotokana na mali | -7.43% | — |
Faida inayotokana mtaji | -7.87% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Mac 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -7.64M | -597.53% |
Pesa kutokana na shughuli | -3.52M | -138.41% |
Pesa kutokana na uwekezaji | 23.62M | -21.27% |
Pesa kutokana na ufadhili | — | — |
Mabadiliko halisi ya pesa taslimu | 20.10M | 111.07% |
Mtiririko huru wa pesa | elfu -295.50 | 80.34% |
Kuhusu
Oramed Pharmaceuticals Inc., is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2006
Tovuti
Wafanyakazi
13
